Troy Edward Wilson
Net Worth
Last updated:
What is Troy Edward Wilson net worth?
The estimated net worth of Dr. Troy Edward Wilson is at least $25,473,121 as of 6 Sep 2025. He owns shares worth $4,097 as insider, has earned $16,457,024 from insider trading and has received compensation worth at least $9,012,000 in Avidity Biosciences, Inc. and Kura Oncology, Inc..
What is the salary of Troy Edward Wilson?
Dr. Troy Edward Wilson salary is $1,110,000 per year as Chairman, Chief Executive Officer & Pres in Kura Oncology, Inc.. He also receives $132,000 as Co-Founder & Chairman in Avidity Biosciences, Inc..
How old is Troy Edward Wilson?
Dr. Troy Edward Wilson is 56 years old, born in 1969.
What stocks does Troy Edward Wilson currently own?
As insider, Dr. Troy Edward Wilson owns shares in one company:
Company | Title | Shares | Price per share | Total value |
---|---|---|---|---|
Kura Oncology, Inc. (KURA) | Chairman, Chief Executive Officer & Pres | 559 | $7.33 | $4,097 |
What does Kura Oncology, Inc. do?
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A protein-protein interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; and tipifarnib, an orally bioavailable inhibitor of farnesyl transferase that is in Phase II clinical trials for the treatment of solid tumors and hematologic indications. The company has a clinical collaboration with Novartis to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression or PIK3CA mutation and/or amplification. Kura Oncology, Inc. was founded in 2014 and is headquartered in San Diego, California.
Troy Edward Wilson insider trading
Kura Oncology, Inc.
Dr. Troy Edward Wilson has made 18 insider trades between 2017-2024, according to the Form 4 filled with the SEC. Most recently he sold 84,107 units of KURA stock worth $1,701,485 on 24 Jan 2024.
The largest trade he's ever made was exercising 157,106 units of KURA stock on 8 Oct 2020. As of 6 Sep 2025 he still owns at least 559 units of KURA stock.
Avidity Biosciences key executives
Avidity Biosciences, Inc. executives and other stock owners filed with the SEC:
- Dr. Troy Edward Wilson (56) Co-Founder & Chairman
- Mr. Michael F. MacLean (59) Chief Financial Officer
- Ms. Sarah Boyce (53) Pres, Chief Executive Officer & Director